

PROGRAMME OF LIVE SESSIONS: CET timing

The programme below will take place live. This time schedule corresponds to **CET timing**. [Click here](#) to adapt the CET time schedule to your own time zone.

If you want to ask questions during the Panel Discussions and Round Tables or if you want to test your knowledge and vote during Interactive Case presentations and debates, please make sure that you join us at the times indicated below.

Please also note that the Meet the Expert sessions and the Mentored Poster Walk will take place 100% live. To interact you must be online at the times indicated in the programme below.

Thank you for joining us. We wish you a good meeting



**E-Conference: 2nd How to Diagnose and Treat
CML / MPN
February 25-28, 2021 – #CMLMPN2021
Chairs: Claire Harrison, Andreas Hochhaus, Ruben Mesa**

Thursday, February 25th, 2021

13:55-14:00 Welcome

SESSION I – Optimizing cytoreduction

Chair: Jean-Jacques Kiladjian (Paris)

| | | |
|-------------|---|---|
| 14:00-14:05 | Introduction | Jean-Jacques Kiladjian (Paris) |
| 14:05-14:15 | Interactive case | Jean-Jacques Kiladjian (Paris) |
| 14:15-14:35 | Case-based lecture: Hydroxyurea / Resistance to Hydroxyurea | Alessandro Vannucchi (Florence) |
| 14:35-14:55 | Case-based lecture: Interferon | Heinz Gisslinger (Vienna) |
| 14:55-15:15 | Case-based lecture: Ruxolitinib | Brady L. Stein (Chicago) |
| 15:15-15:25 | Interactive case: Hepcidin Agonists in Polycythemia Vera | Marina Kremyanskaya (New York) |
| 15:25-15:30 | <i>Addition of Parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with Myelofibrosis</i> | <i>Abdulraheem Yacoub (Kansas City)</i> |
| 15:30-16:00 | Panel discussion | |
| 16:00-16:10 | Coffee Break | |

SESSION II – Management of CML with TKI

Chair: François-Xavier Mahon (Bordeaux)

| | | |
|--------------------|---|----------------------------------|
| 16:10-16:15 | Introduction | François-Xavier Mahon (Bordeaux) |
| 16:15-16:25 | Interactive case | François-Xavier Mahon (Bordeaux) |
| 16:25-16:45 | Case-based lecture: First line TKIs | Giuseppe Saglio (Turin) |
| 16:45-17:05 | Case-based lecture: Use of generics | Tomasz Sacha (Krakow) |
| 17:05-17:25 | Case-based lecture: Salvage treatment and other lines | Gianantonio Rosti (Bologna) |
| 17:25-17:35 | Interactive case | Peter E. Westerweel (Dordrecht) |
| 17:35-17:40 | <i>Assessment of individual molecular response in Chronic Myeloid Leukemia patients with atypical BCR-ABL1 fusion transcripts. Recommendations by the EUTOS Cooperative Network</i> | <i>Vivien Günther (Jena)</i> |
| 17:40-18:10 | <i>Panel discussion</i> | |
| 18:20-19:20 | Mentored poster walk | |
| | Leaders: John Mascarenhas (New York)*, Franck Nicolini (Lyon)* | |

Friday, February 26th, 2021

13:00-14:00 **SATELLITE SYMPOSIUM**

Shifting the paradigm in myelofibrosis care

Speakers: Ruben Mesa (San Antonio), Adam Mead (Oxford)

This educational symposium is organized and funded by AbbVie

SESSION III – MPN risk stratification including vascular events

Chair: Francesco Passamonti (Varese)

| | | |
|--------------------|---|-------------------------------|
| 14:10-14:15 | Introduction | Francesco Passamonti (Varese) |
| 14:15-14:25 | Interactive case: MPN risk stratification | Francesco Passamonti (Varese) |
| 14:25-14:45 | Case-based Lecture: Essential Thrombocythemia | Alberto Alvarez (Barcelona) |
| 14:45-15:05 | Case-based lecture: Polycythemia Vera | Naseema Gangat (Rochester) |
| 15:05-15:25 | Case-based lecture: Pre-Myelofibrosis & Myelofibrosis | Paola Guglielmelli (Florence) |
| 15:25-15:45 | Case-based lecture: Vascular risk assessment in MPN | Emmanuel Messas (Paris) |
| 15:45-16:10 | <i>Panel discussion</i> | |
| 16:10-16:20 | Coffee break | |

16:20-17:15 DEBATE 1 – Interferon alpha should be front line therapy in all ET/PV patients
Chair: Ruben Mesa (San Antonio)

16:20-16:25 Introduction Ruben Mesa (San Antonio)

Audience votes YES or NO

16:25-16:40 Yes Florian Heidel (Greifswald)

16:40-16:55 No Claire Harrison (London)

16:55-17:15 Discussion

Audience votes again YES or NO

17:15-18:25 ROUNDTABLE 1 – Infections in myeloproliferative disorders, including CML
Chair: Ruben Mesa (San Antonio)

17:15-17:20 Introduction Ruben Mesa (San Antonio)

17:20-17:35 COVID-19 and CML Delphine Rea (Paris)

17:35-17:50 COVID-19 in MPN Tiziano Barbui (Bergamo)

17:50-18:05 Infections in MPN - patients survey Florian Heidel (Greifswald)

18:05-18:25 Discussion

18:35-19:35 Simultaneous Meet the Experts sessions:

- | | |
|--|---|
| 1. Management of Myelofibrosis & New agents in Myelofibrosis | Srdan Verstovsek (Houston), Ruben Mesa (San Antonio) |
| 2. Clonal Evolution in MPNs | Jyoti Nangalia (Hinxton), Ann Mullally (Boston) |
| 3. Management of mastocytosis | Jason Gotlib (Stanford), Deepti Radia (London) |
| 4. Transplant for challenging MPNs and CML in 2021 | Nicolaus Kröger (Hamburg), Vikas Gupta (Toronto), Donal McLornan (London) |
| 5. How to safely and successfully use social media in medicine | Naveen Pemmaraju (Houston) |

Saturday, February 27th, 2021

09:00-10:00 Simultaneous Meet the Experts sessions:

- | | |
|---|---|
| 1. Management of PV & Lessons learned from Interferon in PV | Heinz Gisslinger (Vienna), Martin Griesshammer (Minden) |
| 2. COVID-19 and MPNs | Tiziano Barbui (Bergamo), Claire Harrison (London) |
| 3. Investigation and management of erythrocytosis | Mary Frances McMullin (Belfast) |
| 4. Investigation and management of eosinophilia | Andreas Reiter (Mannheim) |

10:00-10:10 Coffee Break and Poster viewing

10:10-11:20 ROUNDTABLE 2 – Pregnancy and parenting
Chair: Jane Apperley (London)

| | | |
|-------------|--|-------------------------------|
| 10:10-10:15 | Introduction | Jane Apperley (London) |
| 10:15-10:30 | Pregnancy and TKI | Elisabetta Abruzzese (Rome) |
| 10:30-10:45 | Russian recommendations to manage pregnancy in CML | Ekaterina Chelysheva (Moscow) |
| 10:45-11:00 | Interferon alpha in pregnancy | Martin Griesshammer (Minden) |
| 11:00-11:20 | <i>Discussion</i> | |

11:20-12:15 DEBATE 2 – Allogeneic stem cell transplantation should be considered third line option in chronic phase CML
Chair: Andreas Hochhaus (Jena)

| | | |
|-------------|--------------|-------------------------|
| 11:20-11:25 | Introduction | Andreas Hochhaus (Jena) |
|-------------|--------------|-------------------------|

Audience votes YES or NO

| | | |
|-------------|-----|------------------------|
| 11:25-11:40 | Yes | Jane Apperley (London) |
|-------------|-----|------------------------|

| | | |
|-------------|----|----------------------|
| 11:40-11:55 | No | Delphine Rea (Paris) |
|-------------|----|----------------------|

11:55-12:15 *Discussion*

Audience votes again YES or NO

12:15-13:55 Lunch

12:45-13:45 **SATELLITE SYMPOSIUM**
Optimizing Treatment of Classical MPNs and Exploring New Options in CML
Chair: Claire Harrison (London)
Speakers: Martin Griesshammer (Minden), Massimo Breccia (Rome)

This educational symposium is organized and funded by Novartis

SESSION IV – Evolving therapies in Myelofibrosis
Chair: Ruben Mesa (San Antonio)

| | | |
|-------------|--|----------------------------|
| 13:55-14:00 | Introduction | Ruben Mesa (San Antonio) |
| 14:00-14:10 | Interactive case: Therapy of Myelofibrosis with approved agents | Ruben Mesa (San Antonio) |
| 14:10-14:30 | Case-based lecture: Other JAK inhibitors (Momelotinib, Pacritinib) | Adam Mead (Oxford) |
| 14:30-14:50 | Case-based lecture: JAK inhibitors in combination | Srdan Verstovsek (Houston) |

2/02/21

| | | |
|-------------|--|----------------------------------|
| 14:50-15:10 | Case-based lecture: Other agents | John Mascarenhas (New York) |
| 15:10-15:20 | Interactive case: When to switch from Ruxolitinib | Haifa Kathrin Al-Ali (Halle) |
| 15:20-15:25 | <i>Genomic analysis of primary and secondary Myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study</i> | <i>Damien Luque Paz (Angers)</i> |
| 15:25-15:55 | <i>Panel discussion</i> | |

SESSION V – Management of advanced and unusual disease (MPN and CML)

Chair: Claire Harrison (London)

| | | |
|--------------------|---|--------------------------------------|
| 15:55-16:00 | Introduction | Claire Harrison (London) |
| 16:00-16:20 | Case-based lecture: Management of rare translocations MPN entities FGFR1 and JAK2 partner genes | Andreas Reiter (Mannheim) |
| 16:20-16:40 | Case-based lecture: Transplantation in Myelofibrosis & CML in advanced phase | Nicolaus Kröger (Hamburg) |
| 16:40-17:00 | Case-based lecture: Myelofibrosis transforming to AML (agents & approaches) | Vikas Gupta (Toronto) |
| 17:00-17:20 | Case-based lecture: Blast crisis in CML | Dragana Milojkovic (London) |
| 17:20-17:30 | Interactive case: CMML | Donal McLornan (London) |
| 17:30-17:40 | Interactive case: Venetoclax data | Srdan Verstovsek (Houston) |
| 17:40-17:45 | <i>Cpi-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis patients: update of manifest Phase 2 study</i> | <i>Francesco Passamonti (Varese)</i> |
| 17:45-18:00 | <i>Panel discussion</i> | |
| 18:05-19:05 | Slot for a satellite symposium (already booked) | |

Sunday, February 28th, 2021

SESSION VI – Treatment free remission in CML

Chair: Susanne Saussele (Mannheim)

| | | |
|-------------|---|-----------------------------|
| 09:25-09:30 | Introduction | Susanne Saussele (Mannheim) |
| 09:30-09:40 | Interactive case: Prognostic factors for successful TFR | Susanne Saussele (Mannheim) |
| 09:40-10:00 | Case-based lecture: New technologies in monitoring | Nick Cross (Southampton) |
| 10:00-10:20 | Case-based lecture: New treatments for stem cell eradication | Thomas Ernst (Jena) |

2/02/21

- 10:20-10:40 Case-based lecture: Interferon alpha Andreas Burchert (Marburg)
- 10:40-10:50 Interactive case: Treatment-free remission strategy in CP CML in 2021 Franck Nicolini (Lyon)
- 10:50-11:00 Interactive case: Blastic plasmacytoid dendritic cell neoplasms Naveen Pemmaraju (Houston)
- 11:00-11:05 *The CRISPR/Cas9 system abolishes the tumorigenic ability of BCR/ABL and restoring the normal haematopoiesis in the bone marrow niche of NOD/SCID mice* Elena Vuelta (Salamanca)
- 11:05-11:35 *Panel discussion*
- 11:35-12:20 Keynote lecture**
Chair: Claire Harrison (London)
- 11:35-11:40 Introduction Claire Harrison (London)
- 11:40-12:00 The origins of MPN Jyoti Nangalia (Hinxton)
- 12:00-12:10 Discussion
- 12:10-12:15 Closing remarks**

MEETING CLOSURE

**Pending confirmation*